Trial Profile
Efficacy and Safety of Coadministered Irbesartan and Atorvastatin in Patients With Hypertension and Hyperlipidemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2016
Price :
$35
*
At a glance
- Drugs Atorvastatin/irbesartan (Primary) ; Atorvastatin; Irbesartan
- Indications Hyperlipidaemia; Hypertension
- Focus Therapeutic Use
- Sponsors Hanmi Pharmaceutical
- 11 Oct 2016 Primary endpoint has been met. (Change from baseline to 8 week in Blood Pressure. [ Time Frame: baseline and 8 week ] [ Designated as safety issue: No ]), according to results published in the Clinical Therapeutics.
- 11 Oct 2016 Primary endpoint has been met. (Percent change from baseline to 8 week in LDL-Cholesterol [ Time Frame: baseline and 8 week ] [ Designated as safety issue: No ]), according to results published in the Clinical Therapeutics.
- 11 Oct 2016 Results published in the Clinical Therapeutics